Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 21

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 21
---
 of the Record Date, the number of authorized shares of our Common Stock was 1,000,000,000 shares, which will not be affected by the Reverse Stock Split. The additional available shares would be available for issuance from time to time at the discretion of the Board when opportunities arise, without further stockholder action or the related delays and expenses, except as may be required for a particular transaction by law, the rules of any exchange on which our securities may then be listed, or other agreements or restrictions. There are no preemptive rights relating to the Common Stock. As such, any issuance of additional shares of Common Stock would increase the number of outstanding shares of Common Stock and (unless such issuance was pro rata among existing stockholders) the percentage ownership of existing stockholders would be diluted accordingly. 10

The table below illustrates certain, but not all, possible reverse stock split ratios, together with the implied number of issued and outstanding shares of the Common Stock resulting from implementation of the Reverse Stock Split based onshares of the Common Stock outstanding as of the Record Date.

| Example Ratios within Delegated Range of Ratios |     |       Implied 
   Approximate 
     Number of 
    Issued and 
   Outstanding 
     Shares of 
  Common Stock 
 Following the 
 Reverse Stock 
      Split(1) |
| 1-for-40                                        |     |       520,067 |
| 1-for-70                                        |     |       297,181 |
| 1-for-100                                       |     |       208,027 |
| 1-for-125                                       |     |       166,421 |
| 1-for-150                                       |     |       138,685 |

____________ (1)Excludes the effect of fractional share treatment. We are exploring various sources of financing, including through potential future sales of Common Stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of Common Stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern. As of the Record Date, we had 20,802,671 shares of Common Stock issued and outstanding, 74,151 shares of Common Stock reserved for issuance upon the exercise of outstanding options, 159,724shares of